13 terminated. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Terminated 13 |
| Phase 2 | 2 | Terminated 2 |
Follow Uveitis: new trials by email Literature Review of Uveitis trials Research Report on Uveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert Sham Injector, FAI Insert - Uveitis, Uveitis, Posterior | Phase 3 | Terminated | EyePoint Pharmaceuticals, Inc. | 12 | 2021-10-13 | 2024-12-19 |
| Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF intravitreal injection of Conbercept - Uveitis, Macular Edema | Phase 2 / Phase 3 | Terminated | Peking Union Medical College Hospital | 5 | 2019-10-12 | 2022-10-25 |
| Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis Placebo, Gevokizumab - Behcet's Disease Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 4 | 2014-11-01 | 2015-12-29 |
| Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Gevokizumab - Chronic Uveitis | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 71 | 2014-08-01 | 2020-01-03 |
| An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Dose 2 gevokizumab - Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 69 | 2014-03-01 | 2015-10-16 |
| Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab - Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 281 | 2012-10-01 | 2016-07-12 |
| Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab - Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 200 | 2012-08-01 | 2016-04-08 |
| Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis AIN457, Placebo - Non-infectious Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 86 | 2010-08-01 | 2016-01-14 |
| Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema bevacizumab, triamcinolone acetonide - Uveitis | Phase 3 | Terminated | Hospital Clinic of Barcelona | 5 | 2010-04-01 | 2012-03-23 |
| Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis AIN457, Placebo - Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 30 | 2010-04-01 | 2015-11-03 |
| 38 Week Extension Study to CAIN457C2303 AIN457, Placebo AIN457 - Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 59 | 2010-03-01 | 2016-02-22 |
| Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis AIN457, Placebo - Non-infectious Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 125 | 2010-02-01 | 2015-11-05 |
| A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis Dexamethasone - Anterior Uveitis | Phase 2 / Phase 3 | Terminated | Allergan | 5 | 2006-05-01 | 2011-05-30 |
Uveitis, Intermediate (8) · Uveitis, Posterior (8) · Panuveitis (6) · Behcet Syndrome (1) · Cardiovascular Diseases (1) · Dermatitis (1) · Macular Edema (1) · Myocardial Infarction (1) · Psoriasis (1) · Uveitis, Anterior (1)
Eye Diseases (13) · Uveal Diseases (13) · Panuveitis (4) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Vascular Diseases (2) · Cardiovascular Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Heart Diseases (1) · Hereditary Autoinflammatory Diseases (1) · Infarction (1) · Ischemia (1) · Macular Degeneration (1) · Mouth Diseases (1)
secukinumab (4) · gevokizumab (2) · Bevacizumab (1) · Bulk Drugs (1) · Dexamethasone (1) · Triamcinolone Acetonide (1)
Novartis Pharmaceuticals (4) · XOMA (US) LLC (4) · Allergan (1) · EyePoint Pharmaceuticals, Inc. (1) · Hospital Clinic of Barcelona (1) · Institut de Recherches Internationales Servier (1) · Peking Union Medical College Hospital (1)
United States (10) · Spain (8) · Germany (7) · Israel (6) · United Kingdom (6) · France (5) · Turkey (Türkiye) (5) · Brazil (4) · Greece (4) · Taiwan (4) · Tunisia (4) · Australia (3) · China (3) · India (3) · Italy (3)
2009 (4)